/ /

CLINICAL

TNF inhibitor treatment tacticsWith a long history in dermatology and rheumatology, TNF inhibitors can not only improve psoriasis and psoriatic arthritis, but they also may reduce comorbid cardiovascular risks and work better combined with methotrexate. Low doses of cyclosporine may be effective at treating the psoriasis reaction when topicals have proven ineffective. Aggressively managing TNF-induced reactions can help patients stay on drugs that are working for other challenging diseases.
Psoriasis and skin cancerCyclosporine and PUVA clearly increase the risk of squamous cell carcinomas, and there is evidence that TNF blockers and methotrexate may do so to a lesser degree. UVB phototherapy has not been shown to cause skin cancer. Acitretin offers protection against the development of basal cell and squamous cell carcinomas.
Guidelines for life after LEAPAs the number of infants and children developing peanut allergy continues to grow, so does the need for pediatricians and other primary care providers to understand current recommendations on how best to prevent this allergy.
Diagnostic & Therapeutic Guidance for Atopic Dermatitis
Diagnostic & Therapeutic Guidance for Atopic DermatitisThe April Table of the Month discusses diagnostic and therapeutic tips for AD patients.
9 Newly Approved Novel Drugs
9 Newly Approved Novel DrugsIt's still early in 2017, but the FDA has been approving drugs left and right. Here's what you need to know.
Targeted treatments for atopic dermatitisEmerging treatments are expected to help fill the need for safer and more effective therapies for atopic dermatitis (AD). Both systemic and topical treatments are needed to provide full and complete treatment for patients with AD. Targeting the specific axis or axes that control AD may contribute to developing personalized approaches to treatment
March Clinical Considerations for NPs, PAsThis month we’re looking at some allergy guideline recommendations, discuss whether or not ‘natural’ soap is milder and novel immunomodulaters.
Brodalumab approved for psoriasisDr. Mark Lebwohl talks about the FDA’s approval of the anti-interleukin-17 receptor monoclonal antibody brodalumab (Siliq, Valeant Pharmaceuticals) for treatment of adults with moderate-to-severe plaque psoriasis.
Psoriasis underdiagnosed, undertreatedIn skin of color, psoriasis can be tough to spot, and it carries a broader differential diagnosis. Darker-skinned patients may not know that they can develop psoriasis, or the importance of seeking treatment early.
Research gaps persist in psoriasis, psoriatic arthritisBeing able to predict which patients will respond to which treatments will help dermatologists in treating psoriasis, preventing progression to psoriatic arthritis and reducing comorbidities.

Poll

View Results